Original Investigation
Heart-After-Liver Transplantation Attenuates Rejection of Cardiac Allografts in Sensitized Patients

https://doi.org/10.1016/j.jacc.2021.01.013Get rights and content
Under an Elsevier user license
open archive

Abstract

Background

In patients undergoing heart transplantation, significant allosensitization limits access to organs, resulting in longer wait times and high waitlist mortality. Current desensitization strategies are limited in enabling successful transplantation.

Objectives

The purpose of this study was to describe the cumulative experience of combined heart-liver transplantation using a novel heart-after-liver transplant (HALT) protocol resulting in profound immunologic protection.

Methods

Reported are the results of a clinical protocol that was instituted to transplant highly sensitized patients requiring combined heart and liver transplantation at a single institution. Patients were dual-organ listed with perceived elevated risk of rejection or markedly prolonged waitlist time due to high levels of allo-antibodies. Detailed immunological data and long-term patient and graft outcomes were obtained.

Results

A total of 7 patients (age 43 ± 7 years, 86% women) with high allosensitization (median calculated panel reactive antibody = 77%) underwent HALT. All had significant, unacceptable donor specific antibodies (DSA) (>4,000 mean fluorescence antibody). Prospective pre-operative flow cytometric T-cell crossmatch was positive in all, and B-cell crossmatch was positive in 5 of 7. After HALT, retrospective crossmatch (B- and T-cell) became negative in all. DSA fell dramatically; at last follow-up, all pre-formed or de novo DSA levels were insignificant at <2,000 mean fluorescence antibody. No patients experienced >1R rejection over a median follow-up of 48 months (interquartile range: 25 to 68 months). There was 1 death due to metastatic cancer and no significant graft dysfunction.

Conclusions

A heart-after-liver transplantation protocol enables successful transplantation via near-elimination of DSA and is effective in preventing adverse immunological outcomes in highly sensitized patients listed for combined heart-liver transplantation.

Key Words

combined organ transplantation
heart transplantation
rejection
sensitization

Abbreviations and Acronyms

AMR
antibody-mediated rejection
ATG
antithymocyte globulin
CAV
cardiac allograft vasculopathy
CHLTx
combined heart and liver transplantation
DSA
donor-specific antibodies
HALT
heart-after-liver transplantation
MFI
mean fluorescence intensity
ProFXM
prospective flow crossmatch
SAB
single antigen bead
TCMR
T-cell mediated rejection

Cited by (0)

Listen to this manuscript's audio summary by Editor-in-Chief Dr. Valentin Fuster on JACC.org.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.